Signadori Bio Raises €11 Million Seed Round to Advance Next-Generation Solid Tumour Platform
Signadori Bio SAS (“Signadori” or the “Company”), a preclinical-stage biopharmaceutical company developing a next generation, off-the-shelf, in vivo engineered, monocyte immunotherapy platform to treat solid tumours, today announced the successful completion of its seed extension financing round, bringing the total raised to €11.1 million. This latest investment was through participation from Taiho Ventures, and existing investors Sofinnova Partners and Invivo Partners.
